 (Circulation 1989;80:1016-1028 
M easurement of ventricular contractility has been an important but elusive goal, both in experimental cardiac mechanics and in the clinical assessment of patients with heart disease. Suga, Sagawa, coworkers, and othersl-6 developed the concept of the end-systolic pressurevolume relation (ESPVR) and suggested that it could be used as an index of global ventricular contractility.
In principle, the measurement of ESPVR is straightforward. It requires only the acquisition of ventricular pressure-volume (PV) loops at two or more preload or afterload conditions. The endsystolic points on these PV loops are identified, and a line is drawn through them; the slope of this line is the end-systolic (peak) elastance or Ema,. Unfortunately, this procedure has been difficult to execute, From the Departments of Bioengineering and Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
Supported by the National Institutes of Health grant HL-36308.except in isolated heart preparations.1,3,7,8 Although intraventricular pressure is easily measured, typically with a catheter-tip manometer, both the determination of ventricular volume and the creation of altered afterload conditions have been problematic. It is for these reasons that the usefulness of the ESPVR measurement has not been fully evaluated for experimental cardiac mechanics or for clinical application.
Previous attempts to measure ESPVR outside of the isolated heart preparation have used pharmacologic or mechanical vasodilators and constrictors to change afterload or preload.5,9-11 Unfortunately, most of these interventions act over extended periods of time and, thus, tend to stimulate physiologic feedback mechanisms that alter cardiac contractility. When blocking agents are used to counter these physiologic feedback mechanisms, there is a possibility of altering ventricular contractility by direct effects of the drugs. Even in the isolated heart preparation, in which vascular, neural, and hormonal connections are severed to prevent reflex alterations in cardiac contractility, the isolated preparation develops changes in the basal contractility of the ventricle.4'12,13 A convenient method of alter-ing afterload without altering ventricular contractility has been difficult to obtain.
To overcome this problem, Bogen et al12 devised a servocontrolled syringe pump that connected to the left ventricle through an apical cannula. When this device was operated in conjunction with an electropneumatic aortic occluder, afterload could be varied for the period of a single heartbeat, thus, providing a range of loading conditions necessary for observing the ESPVR. This approach, however, is still limited. The instrumentation is complicated; repeated measurements of ESPVR in a chronic preparation would be difficult; and the clinical application of the servocontrolled syringe pump seems unlikely. Subsequently, Igarashi and Suga14 designed a similar but simpler technique to measure ESPVR by occluding the aorta using Satinsky's vascular forceps. However, this technique can only be used in acute studies and assumes that ESPVR is linear in all situations. Recently, there have been questions of whether or not it may be more appropriate to fit the ESPVR to a parabolic function.1'516
Therefore, we developed a new technique of measuring ESPVR. This method is simple and allows serial determinations of ESPVR in chronic preparations. Finally, this technique, in which transient variations in afterload are produced by timed inflations of a small intra-aortic balloon, shows promise for clinical measurement of ESPVR.
Methods

Principle of Operation
With the new technique we have developed, ESPVR is determined from a series of ventricular PV loops obtained under varying afterload conditions. Intraventricular pressure is measured by a catheter-tip manometer; ventricular volume is measured by integrating the flow signal from an electromagnetic flow probe located at the aortic root; and changes in afterload are produced by intermittent inflation of a small polyethylene balloon positioned in the ascending aorta. When the balloon is inflated for a single heartbeat, the aorta is occluded, and ventricular ejection is interrupted. By timing the inflation of the balloon with respect to the cardiac cycle, it is possible to interrupt ejection at varying points within the ejection phase. This produces intervention beats, in which systole commences normally but terminates at different ventricular volumes with an isovolumic contraction. Because the occluding balloon is only inflated transiently, reflex changes in cardiac contractility are essentially eliminated.
Aortic Occluder Balloon and Control System
The apparatus consists of the following components: a pneumatically driven intra-aortic catheter balloon, an electrical triggering circuit, and a microprocessor-controlled timing system (Figure 1) .
Balloon catheter. The aortic occluding balloon is a 5-cc polyethylene balloon, with 22-mm (inflated) outer diameter, attached to an 8.5F catheter. This was custom designed and fabricated by DataScope (Oakland, New Jersey). The catheter balloon is inserted into the carotid artery and is positioned approximately 1-2 cm distal to the aortic valve in the aortic root but proximal to the innominate takeoff.
Pneumatic balloon inflator. The occluding balloon is inflated pneumatically by an electropneumatic actuator. The balloon catheter is connected to the output port of a small-bore (1.91 cm) air cylinder (style B-12, Aurora Air Products, Aurora, Illinois). When the piston of this air cylinder (the "inflation cylinder") is pushed inward, air is displaced into the balloon. Piston motion, in turn, is generated by directing compressed air into another identical air cylinder (the "'driving cylinder"). This causes the piston of the driving cylinder to be displaced outward. Because the actuator rods of the two air cylinders are connected in series, compressed air applied to the driving cylinder causes air to be displaced out of the inflation cylinder and into the balloon. For these air cylinders, the actuator rod stroke is 11.43 cm, which corresponds to a maxi- to position the stops.
The pressure of the compressed air source is regulated by a 0-100 psi regulator. In operation, the pressure is set so the balloon can be inflated within a specified time period. Time for inflation is measured by using an electrical switch to detect the contact of the actuator rod against the mechanical stop. The time from the turn-on signal to the solenoid to the actuator stop signal was measured with a digital storage oscilloscope (PM 3310, Philips, Mahwah, New Jersey). It was found that a regulated pressure of 30 psi produced balloon inflations within 26.7±4.1 msec. The inflation time of the balloon is actually somewhat less than this because the measured time includes the delay in solenoid activation.
Electronic triggering and timing. A timing system allows the balloon to be inflated at designated times within the cardiac cycle. Because the coupling between electrocardiographic signals and mechanical contraction is not constant especially in disease states, the control system uses, instead, the ventricular pressure signal to establish the timing reference. Essentially, an analog circuit follows left ventricular pressure and recognizes when ventricular pressure reaches a set fraction of peak pressure. The ventricular pressure signal goes to a peak detector, and its output passes to an adjustable voltage divider. The output ("threshold signal") is, thus, a percentage of peak ventricular pressure. The peak detector circuit has a time constant of one second to filter out sudden fluctuations in peak ventricular pressure. The ventricular pressure signal is then compared with the threshold signal by an analog comparator circuit. When the rising ventricular pressure reaches the threshold value, the output of the comparator undergoes a step change that is tied to the input port on a microprocessor controller. control (normal contractility) and epinephrine administration (enhanced contractility). After each sheep was fully instrumented, occluder triggering and timing parameters were set. First, the trigger threshold (fraction of peak systolic pressure) was set to a point just before ventricular ejection occurred, at approximately 50% of peak systolic pressure. Second, the timing system was programmed to produce an alternating sequence of balloon occlusions and control periods. The sequence consisted of three single-beat occlusions, with intervening control periods of four nonoccluded beats. The occlusions were timed so they occurred just before ejection, at peak systolic pressure, and during the late ejection period. These timings are heart-rate dependent, but for an average heart rate of 100 beats/min, the occlusions were typically at 0, 80, and 125 msec after the trigger point. Inflation duration was set to extend through the early diastolic phase of the following beat; this period was typically 300 msec long.
With these settings and the heart in the control state, pressure-flow data were recorded during the occlusion sequence previously described. For each data-acquisition run, data for 10 more seconds were recorded both before and after the occlusion sequence. If, during data acquisition, a premature contraction occurred or if the occluder timing was not properly set (e.g., because of a change in heart rate), those data were rejected for subsequent analysis, and additional runs were made. A minimum of five acceptable data runs were obtained for each sheep in the normal state.
A state of enhanced contractility was obtained by administering a continuous epinephrine drip at 0.5 ,g/kg/min. After 15 minutes, balloon-occlusion measurements of end-systolic elastance (Emax) were obtained with the same protocol used for the normal heart. Because epinephrine increased the heart rate, the inflation times (delay from threshold trigger and inflation duration) were shortened.
At the conclusion of the protocol, the animals were killed. The hearts were excised. The right ventricular free wall, fat, and valvular tissue were dissected away from the left free wall and the septum, and the remaining left ventricle was weighed. In addition, the ascending aorta, with flow cuff still attached, was removed to calibrate the electromagnetic aortic flow probe. Blood was pumped through this aortic segment by an independently calibrated pump circuit, and the flow-probe value was calibrated against the extracorporeal flow meter.
In a separate protocol, two other sheep were used to track ESPVR after cardiac ischemia. In this protocol, a series of control occlusion runs were a short-acting fl1-blocker, was infused to prevent reflex changes in contractility. The heart was initially loaded with 0.55 mg/kg/min of esmolol for 1 minute and then at a steady infusion rate of 0.33 mg/kg/min. More balloon-occlusion measurements of end-systolic elastance were taken; then, the heart was subjected to 2 minutes of warm global ischemia. The aorta was cross-clamped for 2 minutes, and the heart was allowed to fibrillate. After the clamp was removed, more balloon-occlusion runs were obtained. Finally, end-systolic elastance was measured while administering an epinephrine drip at 0.5 gLg/kg/min. Postmortem measurements and calibrations similar to the previous protocol were obtained at the conclusion of this protocol. 
where Pes and Ves are the end-systolic pressure and volume, respectively.
To find Emnaxand V0, a numerical scheme is used.
First, an initial estimate for V0 is made. Then, for each PV loop, the instantaneous elastance, E(t), is calculated using the equation introduced by Suga and Sagawa3: Figure 2 shows the operation of the balloonoccluder system. Shown are left ventricular pressure and aortic flow traces, in which four different afterload conditions are observed in a normal sheep heart. Four heartbeats are labeled in the figure. The first three correspond to one of the balloon occlusions, and the fourth to a nonoccluded beat. Beat 1 is a nearly isovolumic beat when the occlusion occurred slightly after ventricular ejection began. In beat 2, occlusion occurred at a point that would ordinarily fall in the midejection period; and in beat 3, occlusion occurred late in systole. Therefore, for beat 1 (early occlusion), there is very little aortic flow and a substantial increase (from 83 to 124 mm Hg) in peak systolic pressure. For beat 2 (middle occlusion), aortic flow is reduced in both duration and amplitude, with an integrated flow (ejection volume) of only 55% of normal. For this beat, peak ventricular pressure increased to 106 mm Hg. For beat 3 (late occlusion), aortic flow is somewhat increased compared with beat 2, and peak systolic pressure, at 95 mm Hg, is slightly above normal. Finally, a normal beat (beat 4), unaffected by aortic occlusion, is taken as the fourth afterload condition. Figure 3A shows the PV loops computed from the pressure and flow traces given in Figure 2 . Each loop is labeled as in Figure 2 , and the end-systolic points are indicated by the solid triangles. The volume measure, relative left ventricular volume, is defined as negative integrated aortic flow. Thus, end-diastolic volume is associated with a relative volume of zero. The PV loops for the occluded beats (beats 1-3) initially follow the loop for the unoccluded beat (beat 4) but make a sharp transition to isovolumic systole as the aorta becomes occluded by the balloon. The end-systolic PV relation, given by the straight line in the figure, was calculated by the iterative method previously described. The four end-systolic points fit the line very closely, with a correlation coefficient of 0.99.
The slope of the linear ESPVR, Em, is 3.88 mm Hg/ ml, and the volume intercept, Vi, is -33.13 ml. -20 0 Relotive LV Volume (ml)
To verify that the operation of the occluder did not affect the baseline contractility of the ventricle, a comparison was made between beats before and after occlusion. Pressure and flow data from the five beats immediately preceding the occlusion sequence were averaged together; pressure and flow data from the five beats immediately after the sequence were similarly averaged. Comparisons were made for Pma,x, stroke volume, and the area under the PV ters and end-systolic PV relations were measured under normal and epinephrine-enhanced contractility. The hemodynamic parameters are summarized in Table 1 . As is usual, the heart rate, peak left ventricular pressure, maximum dP/dt, cardiac output, and stroke volume all increased. With epinephrine infusion, the heart rate average increased from 108.05 to 135.07 beats/min. Despite a shortened systolic period with these faster heart rates, the balloon-occluder system continued to function without any difficulty. Stroke Figure 3B . This is the same heart as shown in Figure 3A , and four different afterload conditions are shown as before. The end-systolic points are nearly colinear (correlation coefficient=0.99). The E.,, for this example is 7.74 mm Hg/ml and is 3.88 mm Hg/ml for the normal contractile state, which is nearly a twofold increase in contractility. Table 2 summarizes the measurement of the ESPVR using the linear Equation 1. For each animal, Emax is given for both contractile states, along with the volume intercept, Vi, and statistical information. Contractile states were compared using two types of linear regression analyses to calculate ESPVR. In the first, under the heading "Mean" in Table 2 , Emax, Vi, and the correlation coefficient were computed for each occlusion sequence and the results averaged together. The standard deviation for Emax, therefore, describes the reproducibility of the elastance measurement. Standard deviation ranges were 0.14-0.72 mm Hg/ml in the normal heart, indicating that at a given contractile state the measurement is very repeatable.
The second regression method, under the heading "Pooled" in Table 2 , whereas the curvilinear ESPVRs are generated from the coefficients in Table 3 . Although there was no statistical change in the enhanced state from the normal state in either Vi or V0On5, there seems to be a systematic increase in both the volume intercepts with positive inotropic stimulation. This may be due to increased curvilinearity. For the nonlinear fit of ESPVR, if the parabolic curve was concave toward the volume axis, Vi underestimated the volume-axis intercept (i.e., Vi was more negative than V0,n). On the other hand, Vi overestimated the intercepts for the two animals in which the parabolic curve was convex. The dangers of extrapolating are also evident here. Both the linear and nonlinear curves fit the end-systolic PV data points very well; however, they diverged sub- . Panels A-F correspond to animals 1-6. *, endsystolic pressure-volume (PV) data points from all occlusion runs for normal contractile state in each animal. o, end-systolic PV points for epinephrine-enhanced contractility. -, averaged linear and nonlinear ESPVR fits to data in normal state; ---, ESPVR fits to data in the enhanced states. Linear and nonlinear ESPVR fit end-systolic PVdatapoints very well throughout range in which data were collected. However, when PVpoints are extrapolated beyond data range, there is substantial deviation between linear and nonlinearfits. There also seems to be systematic increase in volume intercepts with enhanced contractility.
Relative LV Volume (ml) stantially when moving away from the data points. Thus, there can be high degrees of disagreement between the linear and nonlinear volume intercepts, with the differences increasing as the absolute value of the coefficient a increases.
ESPVR in the Depressed Contractile State Figure 5 shows how the intermittent balloonocclusion technique can be used to quickly track contractility. The graph is a time trace of Em,, as the heart undergoes: 1) normal "control" period, 15 [mmHg/mil 2) inotropic blocking with esmolol infusion, 3) 2 minutes of global warm ischemia with continued esmolol infusion, and 4) epinephrine infusion after ischemia. Although there was not a substantial change of EmaX from control after onset of esmolol infusion, there did appear to be a trend toward a reduction in Emax, dropping from 9.49 to 5.51 mm Hg/ ml during 21 minutes. The effects of esmolol were noticed after the 2 minutes of ischemia. It blocked any increase in endogenous catecholamines that would be triggered after heart failure. Experimentally, ESPVR has also been measured by mechanical alterations of ventricular load. The use of external aortic clamping devices restrict their application to open-chest preparations.n1214 A number of investigators have also used vena caval occlusions to vary preload.10""'3,27,28 The caval occlusion technique has two potentially serious drawbacks. First, because caval occlusion reported in some studies lasts 12-20 seconds, reflex changes in cardiac contractility may occur. Kass et al13 noticed hysteresis in ESPVR using caval occlusions lasting only 6 seconds. That is, ESPVR defined by the caval occlusions was significantly different from ESPVR generated from the PV loops obtained during postocclusion recovery. Kass et al13 suggested that the decrease in aortic pressure induced by caval occlusions invoked baroreceptor reflexes that increased the contractile state, and to counteract this effect, they used a combination of autonomic blockade with positive inotropic agents. The second drawback with caval occlusion is that it changes both right and left ventricular preload so that ventricular interaction may contribute to the observed ESPVR. In contrast, transient aortic occlusion does not affect ventricular interaction.
Effects ofAltered Inotropic State
We found that increases in inotropic state produced by epinephrine infusion directly related to changes in ESPVR using both linear and secondorder polynomial analyses. Epinephrine increased Ema by an average factor of 2.13+±0.70 (Table 2) .
Comparable increases of Em,,, with catecholamines have been shown in both isolated and intact preparations. 2, 3, 11, 23, 29 Although the volume intercept was found to be statistically inconsequential (Tables 2 and 3) , we noticed a small but consistent increase in the intercept. Other investigators have reported similar findings.513 However, there may be gross errors inherent in extrapolating a value for the volume intercept, especially in light of recent findings that ESPVR may be curvilinear when evaluated throughout a larger left ventricular pressure range.15,16 Figure 4 shows the substantial deviations in the volume intercept when calculated from linear and nonlinear fits to data collected in typical physiologic ranges.
Technical Limitations
Timing. The timing problem encountered with the occlusion sequence relates primarily to triggering the balloon inflation. A steady heart rate is required before the inflation timing can be programmed. Therefore, when heart rate is changing rapidly or when arrhythmias are present, the balloon may mistrigger. For fast heart rates (above 140 beats/ min), it may also be difficult to produce occlusions at three different times within the ejection cycle. However, in this case, two occlusions can be obtained.
Aortic compliance. With mechanical afterloadaltering devices, the compliance of the aorta may cause underestimation of Emax. The 
Conceptual Limitation
Linearity versus nonlinearity. The conceptual limitation relates to the basic definition of the ESPVR.
As originally proposed by Suga and Sagawa,2'3'6'31 the ESPVR is a load-independent measure of ventricular contractility in isolated hearts. Other investigators, also using isolated heart preparations, have shown that ESPVR is not entirely independent of the contraction mode, especially under conditions of rapid ejection.32 Furthermore, studies in isolated15 and intact'6 hearts have shown some nonlinearity in ESPVR.
Because the clinical applicability of the ESPVR concept may depend on the nonlinearity of the relation, we investigated the nonlinearity in our data. In general, ESPVR was concave toward the volume axis. This agrees with previous investigations.' 5"16 Furthermore, Eloo, the instantaneous maximal elastance at Pes=100 mm Hg, significantly changed with positive inotropic stimulation. Although there was nonlinearity, the statistical significance of a, the coefficient of the Ves' term in Equation 3 was minimal ( Table 3) . As presented in Tables 2 and 3 and Figure  4 , both the linear and nonlinear equations fit the data very well and only diverged when the regression lines were used to extrapolate values outside of the measurement range. This is consistent with previous findings.'6 Therefore, although nonlinearity is present in ESPVR, the linearized ESPVR still may be useful in providing a sensitive measure of contractility. For the physiologic range studied here, the linearized ESPVR showed excellent correlation with the measured data. However, caution should be used 25 There seems little doubt now that cardiac contractility is coupled in some way to myocyte length.39 When cardiac muscle is suddenly stretched, either in an isolated muscle40 or a whole-heart preparation,3,41'42 developed tension or developed pressure follows a biphasic response. This response is an immediate increase in tension or pressure, followed by a more gradual time-dependent increase in tension or pressure until a steady state is reached minutes later. In the whole-heart preparation, there is an additional transient drop in developed pressure interposed between the two periods of pressure rise. Although several explanations for these phenomena have been proposed,39'41"43 length-dependent activation now seems the most likely.39'41 The underlying mechanism may be length-dependent calcium flux40 or length-dependent calcium binding. 44 What is the relevance of these observations to the intermittent aortic occlusion technique described here? First, the interrupted ventricular ejection produced by the occluding balloon is more akin to the sudden increases in ventricular afterload studied by Tucci et a141 in the intact heart. Tucci et a141 found that the response to sudden afterload changes was substantially different from the response to sudden volume dilatation. With volume dilatation, the initial increase in developed pressure was significantly smaller than the final steady-state developed pressure level. With afterload increase, however, the initial developed pressure rise was not significantly different than the final pressure rise.
These findings are similar to those of Lew,42 who reported that, although regional end-systolic pressurelength relations (ESPLRs) were shifted to the left after volume loading of the ventricle, the endsystolic lengths immediately after the load change were not significantly different than the lengths before the intervention. This was true even in hearts blocked with propranolol. Finally, Igarashi et a145 showed that when afterload is suddenly switched from an ejecting mode to an isovolumic mode in an isolated heart preparation, there is no significant decrease in peak pressure between the first isovolumic beat and steady-state isovolumic contractions at a given end-diastolic volume. Thus, it appears that, although the contractility in the first beat after a sudden volume dilatation may not be the same as the steady state contractility, the contractility in the first beat after a sudden afterload increase is the same as the steady state contractility.
Igarashi et a145 did note, however, that transient Emax, determined from the first isovolumic beat and the last fully ejecting beat, increased with an increase in ejection fraction and that, for high ejection fractions (36-57% in their control runs), these transient Emax values were similar to those obtained from steady-state loading. One may then conclude from the results of Tucci et aP41 and Igarashi et a145 that poor ejection fraction affects the last fully ejecting PV loop and not the first transiently loaded isovolumic PV loop. For low ejection fractions, this causes Emax to be underestimated. In our study, we did not measure ejection fraction, but it is unlikely that changes in ejection fraction influenced our Emax measurements. Because poor ejection fractions affect the normally ejecting beat, ejection-rate sensitivity would have resulted in highly nonlinear ESPVR, and this was not observed. Also, if hearts are known to have low ejection fractions, one only has to replace the fourth nonoccluded beat with another transiently occluded beat in the ESPVR calculation.
Future Developments
We have described a new in situ method for measuring peak end-systolic elastance. This simple technique of transiently inflating an intra-aortic balloon eliminates physiologic reflexes that may alter ventricular contractility. Because end-systolic elastance can be obtained within three intermittent beats without altering baseline contractility, the technique allows for serial measurements of cardiac function, even when the contractile state is rapidly changing, as shown in Figure 5 . We believe that this technique can be modified for clinical use but will require a nonsurgical method for the measurement of volume (e.g., flow catheters, cardiac imaging, or the volume conductance catheter46).
